Simultaneous presentation of kawasaki disease and toxic shock syndrome in an adolescent male

Pediatric Infectious Disease Journal

Volumn 15, Issue 12, 1996, Pages 1136-1138

  Dele Davies, H ^a,b,d   Kirk, Val ^b   Jadavji, Taj ^a,b   Kotzin, Brian L ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

Kawasaki disease; staphylococcal toxic shock syndrome; superantigens

Indexed keywords

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; TOXIC SHOCK SYNDROME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; HUMANS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0030457166     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199612000-00021     Document Type: Article

References (14)

1. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome [Comments]. Lancet 1993;342:1385-8.
2. Akiyama T, Yashiro K. Probable role of Streptococcus pyogenes in Kawasaki disease. Eur J Pediatr 1993;152:82-92.
3. Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease with particular emphasis on arterial lesions. Acta Pathol Jpn 1991;41:785-97.
4. Abe J, Kotzin BL, Meissner C, et al. Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med. 1993;177:791-6.
5. Fitzgerald JE, Ricalton NS, Mayer AC, et al. Analysis of clonal CD8+ T cell expansions in normal individuals and patients with rheumatoid arthritis. J Immunol 1995;154:3538-3547.
6. Centers for Disease Control and Prevention. Case definitions for public health surveillance. MMWR 1990;39(RR-13):38-9.
7. Ohno S, Miyajima T, Higuchi M, et al. Ocular manifestations of Kawasaki's disease (mucocutaneous lymph node syndrome). Am J Ophthalmol 1982;93:713-7.
8. Choi Y, Lafferty J, Clements J, et al. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med 1990;172:981-4.
9. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992;267:3315-6.
10. Takei S, Arora Y, Walker S. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91:602-7.
11. Blasczyk R, Westhoff U, Gross-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-90.
12. Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995;72:308-11.
13. Wiesenthal A, Todd J. Toxic shock syndrome in children aged 10 years or less. Pediatrics 1984;74:112-7.
14. Gamillscheg A, Zobel G, Karpf EF, et al. Atypical presentation of Kawasaki disease in an infant. Pediatr Cardiol 1993;14:223-6.